Virpax Reports Positive Probudur Results with US Army for Combat Care Study

2025-02-14 08:25:04 ET

DENVER, Colo., Feb 14, 2025 ( 247marketnews.com )- Virpax Pharmaceuticals (NASDAQ: VRPX ) completed a full study following the initial Probudur pilot study conducted by the U.S. Army Institute of Surgical Research (USAISR), under a Cooperative Research and Development Agreement (CRADA).

The study aimed to evaluate whether Probudur, a local anesthetic, could reduce pain behaviors in a rat model of incisional pain. The study followed the same surgical procedures and assessments as the initial pilot study.

Probudur was compared to free bupivacaine (a commonly used local anesthetic) and EXPAREL (another extended-release formulation of bupivacaine).

Various concentrations of Probudur injected into tissue around the incision site resulted in reduced incision-induced pain behaviors, suggesting its potential effectiveness in pain management.

The positive results from this study are consistent with previous observations by Virpax and encourage the company as they continue to develop Probudur as a potential pain management solution. Probudur is designed to reduce or eliminate the need for opioids after surgery, aiming to provide safe and effective pain control during the perioperative period. The local anesthetic works by binding to sodium channels, preventing pain signals from reaching the brain.

In preclinical studies, Probudur has shown long-duration pain control for at least 96 hours. In the rat incisional model, analgesia lasted up to five days. In vitro studies demonstrated that Probudur has a slow-release mechanism that can release bupivacaine for up to six days, making it a promising option for extended pain relief.

The post Virpax Reports Positive Probudur Results with US Army for Combat Care Study appeared first on 24/7 MarketNews .

For further details see: